Taysha Gene Therapies, Inc. (TSHA)
4.25
+0.24
(+5.98%)
USD |
NASDAQ |
Oct 27, 16:00
4.16
-0.09
(-2.12%)
After-Hours: 06:13
Taysha Gene Therapies Price to Book Value : 3.57 for Oct. 27, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| October 27, 2026 | 3.57 |
| October 26, 2026 | 3.368 |
| October 23, 2026 | 3.326 |
| October 22, 2026 | 3.364 |
| October 21, 2026 | 3.461 |
| October 20, 2026 | 3.452 |
| October 19, 2026 | 3.310 |
| October 16, 2026 | 3.041 |
| October 15, 2026 | 3.133 |
| October 14, 2026 | 2.948 |
| October 13, 2026 | 3.007 |
| October 12, 2026 | 3.478 |
| October 09, 2026 | 3.772 |
| October 08, 2026 | 3.721 |
| October 07, 2026 | 3.721 |
| October 06, 2026 | 3.688 |
| October 05, 2026 | 3.772 |
| October 02, 2026 | 3.889 |
| October 01, 2026 | 3.982 |
| September 30, 2026 | 4.091 |
| September 29, 2026 | 4.192 |
| September 28, 2026 | 4.192 |
| September 25, 2026 | 3.923 |
| September 24, 2026 | 4.024 |
| September 23, 2026 | 4.124 |
| Date | Value |
|---|---|
| September 22, 2026 | 4.334 |
| September 21, 2026 | 4.234 |
| September 18, 2026 | 4.217 |
| September 17, 2026 | 4.334 |
| September 16, 2026 | 4.259 |
| September 15, 2026 | 4.250 |
| September 14, 2026 | 4.208 |
| September 11, 2026 | 4.217 |
| September 10, 2026 | 4.334 |
| September 09, 2026 | 4.486 |
| September 08, 2026 | 4.603 |
| September 04, 2026 | 4.704 |
| September 03, 2026 | 4.679 |
| September 02, 2026 | 4.738 |
| September 01, 2026 | 4.788 |
| August 31, 2026 | 4.780 |
| August 28, 2026 | 4.847 |
| August 27, 2026 | 5.006 |
| August 26, 2026 | 5.057 |
| August 25, 2026 | 5.208 |
| August 24, 2026 | 5.015 |
| August 21, 2026 | 5.116 |
| August 20, 2026 | 5.132 |
| August 19, 2026 | 5.401 |
| August 18, 2026 | 5.200 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Altimmune, Inc. | 0.8366 |
| Protalix Biotherapeutics, Inc. | 2.855 |
| Humacyte, Inc. | 3.966 |
| Agenus, Inc. | -- |
| Amgen, Inc. | 20.72 |
Price to Book Value Related Metrics
| PS Ratio | 266.16 |
| PEG Ratio | -0.4661 |
| Price | 4.25 |
| Earnings Yield | -10.17% |
| Market Cap | 1.383B |
| PEGY Ratio | -0.4661 |